167.80
1.03%
-1.74
After Hours:
167.80
Abbvie Inc stock is currently priced at $167.80, with a 24-hour trading volume of 3.81M.
It has seen a -1.03% decreased in the last 24 hours and a -5.97% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $169.4 pivot point. If it approaches the $167.2 support level, significant changes may occur.
Previous Close:
$169.54
Open:
$168.52
24h Volume:
3.81M
Market Cap:
$297.11B
Revenue:
$54.32B
Net Income/Loss:
$4.86B
P/E Ratio:
45.97
EPS:
3.65
Net Cash Flow:
$22.06B
1W Performance:
+2.16%
1M Performance:
-5.97%
6M Performance:
+14.69%
1Y Performance:
+2.27%
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
847-932-7900
Address
1 North Waukegan Road, North Chicago, IL
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
Oct-20-23 | Resumed | UBS | Neutral |
Sep-29-23 | Initiated | Raymond James | Outperform |
Jul-25-23 | Initiated | William Blair | Mkt Perform |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-05-23 | Downgrade | Argus | Buy → Hold |
Mar-01-23 | Initiated | Guggenheim | Buy |
Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
May-23-22 | Initiated | SVB Leerink | Underperform |
May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
Apr-06-22 | Resumed | Morgan Stanley | Overweight |
Feb-28-22 | Downgrade | UBS | Buy → Neutral |
Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
Feb-03-22 | Reiterated | Barclays | Equal Weight |
Feb-03-22 | Reiterated | BofA Securities | Neutral |
Feb-03-22 | Reiterated | Goldman | Neutral |
Jan-13-22 | Initiated | Redburn | Buy |
Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
Dec-09-21 | Resumed | Wells Fargo | Overweight |
Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
Jul-27-21 | Resumed | Truist | Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Nov-10-20 | Resumed | Bernstein | Outperform |
Sep-29-20 | Initiated | Berenberg | Hold |
Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jun-02-20 | Upgrade | Argus | Hold → Buy |
May-18-20 | Resumed | BofA/Merrill | Neutral |
May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-20 | Resumed | Morgan Stanley | Overweight |
Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Feb-06-20 | Initiated | Mizuho | Buy |
Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-26-19 | Reiterated | Cowen | Outperform |
Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
May-28-19 | Initiated | Goldman | Neutral |
Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Zacks Investment Research
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks Investment Research
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks Investment Research
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks Investment Research
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
Abbvie Inc Stock (ABBV) Financials Data
Abbvie Inc (ABBV) Revenue 2024
ABBV reported a revenue (TTM) of $54.32 billion for the quarter ending December 31, 2023, a -6.44% decline year-over-year.
Abbvie Inc (ABBV) Net Income 2024
ABBV net income (TTM) was $4.86 billion for the quarter ending December 31, 2023, a -58.91% decrease year-over-year.
Abbvie Inc (ABBV) Cash Flow 2024
ABBV recorded a free cash flow (TTM) of $22.06 billion for the quarter ending December 31, 2023, a -9.02% decrease year-over-year.
Abbvie Inc (ABBV) Earnings per Share 2024
ABBV earnings per share (TTM) was $2.73 for the quarter ending December 31, 2023, a -58.70% decline year-over-year.
Abbvie Inc Stock (ABBV) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Mar 20 '24 |
Sale |
176.30 |
21,082 |
3,716,757 |
55,903 |
Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER |
Mar 18 '24 |
Option Exercise |
61.36 |
26,110 |
1,602,110 |
119,890 |
Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER |
Mar 18 '24 |
Sale |
178.79 |
58,949 |
10,539,508 |
60,941 |
RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER |
Mar 01 '24 |
Option Exercise |
61.36 |
45,700 |
2,804,152 |
89,517 |
RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER |
Mar 01 '24 |
Sale |
177.27 |
75,680 |
13,415,503 |
13,837 |
Michael Robert A. | PRES & CHIEF OPERATING OFFICER |
Feb 29 '24 |
Option Exercise |
58.30 |
21,560 |
1,257,012 |
167,524 |
Michael Robert A. | PRES & CHIEF OPERATING OFFICER |
Feb 29 '24 |
Sale |
176.45 |
68,879 |
12,153,957 |
98,645 |
Siatis Perry C | EVP, GC AND SECRETARY |
Feb 29 '24 |
Sale |
177.39 |
9,891 |
1,754,555 |
10,397 |
Buckbee Kevin K | SVP, CONTROLLER |
Feb 29 '24 |
Sale |
176.65 |
5,144 |
908,688 |
6,983 |
GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO |
Feb 28 '24 |
Sale |
177.27 |
138,616 |
24,572,458 |
519,099 |
About Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; and Bristol-Myers Squibb Company. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Cap:
|
Volume (24h):